obesity drugs
Coverage of obesity drugs in the Nexus archive.
- Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
Medicare has started covering obesity drugs for the first time, and companies like Walmart and CVS Health are assisting seniors in navigating this coverage.
- Medicare offers access to popular obesity drugs for $50 a month
Medicare is providing beneficiaries access to popular obesity drugs with a $50 monthly copay. The program requires patients to meet specific criteria and is a temporary initiative set to last through 2027.
- Medicare will start covering obesity drugs for the first time. Here's what patients should know
Medicare will begin covering obesity drugs for the first time, potentially expanding access for seniors and creating new patient opportunities for Novo Nordisk and Eli Lilly.
- Obesity drugs approach a major milestone, and Lilly may have a 'game changer' ahead
Obesity drugs are nearing a major milestone, and pharmaceutical company Lilly may have a significant breakthrough ahead. The Investing Club's Homestretch update highlights this development as part of its daily financial analysis.
- STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end
Weight loss drugs will become available to Medicare beneficiaries aged 65+ next month through a temporary government program. The Trump administration is bypassing a law prohibiting Medicare from covering obesity drugs by using a demonstration program, extending a transitional 'Bridge' program until 2024 after private insurers refused to participate in the original three-year 'BALANCE' plan.
- Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies provide lifestyle support to help individuals taking obesity drugs achieve weight loss success. Employers, however, are pressuring these telehealth providers to restrict spending on the drugs.
- Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies provide lifestyle support to maximize weight loss success for individuals taking obesity drugs. Employers, however, are urging these providers to restrict spending on such medications.
- Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are competing to enter the obesity drug market currently dominated by Novo Nordisk and Eli Lilly. The article highlights the pharmaceutical industry's interest in this lucrative sector.
- STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
The article discusses updates on competition in obesity drugs, insights on eating disorders, new information on a BCG vaccine, and a clarification from the American Diabetes Association regarding a police incident. It is part of STAT’s coverage from the ADA annual conference.
- Daily briefing: A treatment to reverse cellular ageing is about to be tested in people
A treatment called 'partial reprogramming' that reverses cellular aging is set for clinical trials in 2026. The study, published in Nature, also explores DNA modifications in mice and variations in obesity drug effectiveness.
- Why obesity drugs work better for some people: these genes hold clues
A study of nearly 28,000 people reveals genetic factors influencing the effectiveness of obesity drugs and their gastrointestinal side effects. Researchers identified specific genetic variants linked to varying responses to GLP-1 medications.